Clinical Trials Sponsored by Merus N.V.

Total 1493 results

Merus N.V.

Recruiting

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Metastatic Castration-resistant Prostate Cancer | NSCLC Harboring NRG1 Fusion

United States
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Merus N.V.

Recruiting

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NSCLC Harboring NRG1 Fusion | Solid Tumours Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion

Spain, France, Israel, Belgium, Denmark, United States, Korea, Republic of, Japan, Germany, Netherlands, Austria, Canada, Italy, Norway, Singapore, Sweden, Taiwan, United Kingdom
Merus N.V.

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic

United States, France, Belgium, Spain, United Kingdom, Netherlands, Portugal
Merus N.V.

Available

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Solid Tumor, Unspecified, Adult | Unknown Primary Tumors | NRG1 Fusion
Merus N.V.

Active, not recruiting

MCLA-117 in Acute Myelogenous Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Italy, Netherlands, Belgium, France
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Cerus Corporation

Completed

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

Healthy

United States
Cerus Corporation

Completed

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

Healthy
Cerus Corporation

Active, not recruiting

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI)

Anemia

United States
Cerus Corporation

Terminated

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

Acute Ebola Virus Disease

United States
Cerus Corporation

Completed

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Thalassemia Major

Turkey, Italy
Cerus Corporation

Terminated

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

Healthy

United States
Cerus Corporation

Completed

Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days (TESSI)

Thrombocytopenia

United Kingdom
Cerus Corporation

Recruiting

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)

Anemia

United States, Puerto Rico
Cerus Corporation

Completed

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components (PIPER)

Transfusion Related Acute Lung Injury

United States
Cerus Corporation

Completed

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells (S303 RBC)

Focus: Assess Post Infusion Viability of S303 RBCs

United States
Cerus Corporation

Completed

Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

Focus:Use of S303 RBCs in Patients With Acute Anemia

Germany
Cerus Endovascular, Ltd

Terminated

Pilot Study of the Contour Neurovascular SystemTM

Intracranial Aneurysm
Cerus Endovascular, Ltd

Terminated

INCA: Intracranial Aneurysm Treatment With NeXsys (INCA)

Intracranial Aneurysm

Argentina
Cerus Endovascular, Ltd

Completed

Coil Assisted Flow Diversion Safety and Performance Study (CAFI)

Intracranial Aneurysm

Denmark, Austria, Canada, Germany, Switzerland
Cerus Endovascular, Ltd

Withdrawn

Post Market Clinical Follow-up (PMCF)Study of the Contour Neurovascular SystemTM

Intracranial Aneurysm
Cerus Endovascular, Ltd

Completed

Contour Neurovascular System - European Pre-Market Unruptured Aneurysm (CERUS)

Intracranial Aneurysm

Denmark, Germany, Austria
Cerus Endovascular, Ltd

Recruiting

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair (NECC)

Aneurysm, Intracranial

United States
Adenobio N.V

Unknown

Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler

Ischemic Heart Disease

France
TiGenix n.v.

Terminated

A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects (OMCM)

Osteochondral Defects

United Kingdom, Germany, Hungary, Belgium
PharmaNeuroBoost N.V.

Completed

Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

Depression

United Kingdom
PharmaNeuroBoost N.V.

Completed

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Canada
PharmaNeuroBoost N.V.

Completed

POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Schizoaffective Disorder | Chronic Schizophrenia

Belgium
ActoGeniX N.V.

Completed

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

Oral Mucositis

United States
ActoGeniX N.V.

Completed

A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis

Moderately Active Ulcerative Colitis

Canada, Netherlands, Sweden, Belgium
Recoly N.V.

Completed

Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.

Haemophilia A

Russian Federation
TiGenix n.v.

Completed

RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee (TIGACT01)

Articular Cartilage Lesion of the Femoral Condyle

Belgium, Croatia, Germany, Netherlands
Meru Health, Inc.

Completed

Meru Health Program Versus Waitlist Control for Adults With Depression

Depression

United States
Meru Health, Inc.

Completed

RCT of Adjunctive Curcumin and the Meru Health Program

Depression

United States
Merbs, Shannath, M.D., Ph.D.

Completed

Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora

Epiphora

United States
Sequana Medical N.V.

Recruiting

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (MOJAVE)

Heart Failure | Volume Overload

United States
Terumo Europe N.V.

Recruiting

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients (NAGOMI COMPLEX)

Cardiovascular Disease | Ischemic Heart Disease | Coronary Artery Occlusion

Switzerland, Spain, Netherlands, Belgium, United Kingdom, Ireland, Italy, Estonia
Terumo Europe N.V.

Active, not recruiting

Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease (PRIZER)

Superficial Femoral Artery Disease | Popliteal Artery Disease

Spain, Belgium, Germany, France, Netherlands
Terumo Europe N.V.

Completed

Holmium-166 Retrospective Collection of Real-World Data (RECORD)

Hepatocellular Carcinoma | Metastatic Cancer

Netherlands, Germany, Switzerland, Belgium, Spain, Portugal, Italy
Terumo Europe N.V.

Terminated

QuiremSpheres Observational Study (Hope166)

Liver, Cancer of, Non-Resectable

Netherlands, Germany
Sequana Medical N.V.

Withdrawn

Malignant Ascites Alfapump® Study (ProMAS)

Malignant Ascites

United Kingdom
Terumo Europe N.V.

Completed

Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease (KARE)

Coronary Artery Disease | Angioplasty, Transluminal, Percutaneous Coronary

Spain, Germany, Serbia, France, Italy
Terumo Europe N.V.

Completed

Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study (MASTER)

Acute ST Segment Elevation Myocardial Infarction

Brazil, Serbia, Italy, Spain, Macedonia, The Former Yugoslav Republic of
Sequana Medical N.V.

Completed

ALFApump System Versus Standard of Care in Ascites Treatment

Refractory or Recurrent Ascites

Spain, United Kingdom, Italy, France, Austria
Terumo Europe N.V.

Completed

Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery (ADBEE)

UTERINE MYOMAS

Germany
Nipro Europe N.V.

Completed

In Vivo Evaluation of the Nipro Elisio™ Dialyzer

Chronic Kidney Disease

France
Swiss Transfusion SRC
Cerus Corporation

Withdrawn

INTERCEPT Safety Evaluation in Anemic Patients (POINT1africa)

Anemia
Philips Electronics Nederland B.V. acting through...
suAzio N.V.

Completed

Norms and Validation for IntelliSpace Cognition Spanish Version

Cognitive Functioning of Healthy Individuals | Hispanic

United States

Clinical Trials Sponsored by Merus N.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations